Kamari, FDA AS ngumumkeun persetujuan ti Seattle Genetics 'antibodi-ubar conjugate Adcetris (brentuximab vedotin) dina kombinasi kalayan kémoterapi pikeun penderita saméméhna dirawat tahap III atawa IV lymphoma Hodgkin klasik (cHL). Persetujuan ieu ngagambarkeun paningkatan dina rencana pangobatan awal pikeun limfoma Hodgkin canggih anu diwanohkeun kana prakték klinis langkung ti 40 taun ka pengker.
Lymphoma is a type of cancer that begins in the lymphatic system. The immune system helps the body fight infections and diseases. Lymphoma can develop almost anywhere in the body and can spread to nearby lymph nodes. It is divided into two types: Limfoma Hodgkin and non-Hodgkin lymphoma. Most patients with Hodgkin lymphoma belong to the classic type. In this type of lymph node, there are large abnormal lymphocytes (a type of white blood cell). Called Reed-Sternberg cells. Through early intervention, patients with Hodgkin’s lymphoma usually get long-term remission.
Dina sidang klinis, poténsi Adcetris pikeun ngubaran limfoma Hodgkin Palasik disahkeun-panaliti ngarékrut 1,334 pasién anu dirawat anu sateuacanna nampi rata-rata 6 kursus siklus 28 dinten sateuacan. Salajengna, aranjeunna dibagi kana dua kelompok, hiji kelompok nampi Adcetris sareng kémoterapi (AVD), sareng kelompok anu sanés ngan ukur nampi kémoterapi (ABVD). Panilitian nunjukkeun yén pasién anu nampi terapi kombinasi gaduh résiko 23% langkung handap tina kamajuan panyakit, maot, atanapi kabutuhan pikeun ngamimitian pangobatan énggal dibandingkeun sareng pasién anu ngan ukur nampi kémoterapi.
Adcetris combines antibodies and drugs, allowing antibodies to direct drugs to sél limfoma called CD30, approved for treatment of relapsed classic Hodgkin lymphoma, classic Hodgkin lymphoma with high risk of relapse or progression after stem cell transplantation, accepted Systemic anaplastic large cell lymphoma that other treatments are not effective, and primary cutaneous anaplastic large cell lymphoma that does not work with other treatments.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm
